← All trials
NCT04608318
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2020
- Primary completion
- Mar 31, 2027
- Completion date
- Mar 31, 2027
- First posted
- Oct 29, 2020
- Last posted
- Dec 8, 2020
- Enrollment
- 897
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- German CLL Study GroupLead sponsor
- German CLL Study GroupOverall official - principal investigator
- Cancer Trials IrelandCollaborator
- Grupo Español de Leucemia Linfocítica Crónica (GELLC)Collaborator
- Gruppo Italiano Malattie EMatologiche dell'AdultoCollaborator
- Swiss Group for Clinical Cancer ResearchCollaborator
- The Israeli CLL Study Group (ICLLSG)Collaborator
- HOVON - Dutch Haemato-Oncology AssociationCollaborator
- Nordic CLL Study Group (NCLLSG)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.